Member Info for miavoce

Very positive IMO.

1. Redmile clearly confident in supporting Scancell.

2. Removes any funding pressure next year which harms could have used as leverage to get a bargain deal for SCIB

3. Redmile now have option to convert at any time. This implies to me that they see the possibility of a significantly higher SP before 2027 which would make conversion and partial exit a possibility for them.

4. Whilst a conversion and bid is a technical possibility, Redmile could have forced the company hand at the original expiry date of 2025 if they wanted to buy Scancell on the cheap.

EC - it is referring to the highest price paid by the bidder in the preceding 12 months, not the highest price paid by just anybody.

Glycol = Glycan of course

By the time PEGS comes around we will hopefully have had stellar SCOPE results, clear demonstration that Moditope works in triggering a strong immune response, and possibly even more Glycol/AvidiMAb deals. The sp should look a lot less derisory at that point.

Well that explains the rise - 900k trade at 11p just posted.

Maybe the scan of the first iSCIB1+ patient has been done and the results have prompted a few 'in the know' to buy....

Normally our seller would have dropped a few large blocks of stock into this rise. I wonder if they are done ? Looks like stock is very tight and / or somebody has place a very large order.

'How on earth is he going to make £5m in 2H? '

This is the key question Fevertreeman. The perplexing thing is that this figure is 5x the H1 revenue and yet the management have expressed confidence in achieving it. This is either the mother of all wishful thinking OR the management are aware of something which will significantly increase revenue and in which they have very high confidence. I can't believe that the management would be stupid enough for it to the the former, so I'm going with it being the latter.

Will this study not already be finished given that the REC approval was given in Apr 2023 ?

Excellent find. Scancell are clearly serious about progressing this.

Bid has move up despite preponderance of selling...has another large buy order just been placed ?

The fact that the DNA fragments are becoming used in an ever wider range of applications is a real positive indicator for CTC's in the future where we will se an ever increasing range of applications for CTC's (which of course will be to Angle's benefit). A critical pint to bear in mind is the use of DNA fragments and the use of CTC's are not competitors - they are complementary. DNA fragments are used for screening / detection, and CTC's are used to get a detailed picture of the cancer and to monitor its progress / drug response.

It wasn't a UT, it was traded at 15:23 and there were also 2 separate trades. Unlikely to be mm's 'book-squaring', looks like a large PI buy or maybe even an institutional buy.

Thanks EC, I'm already fully familiar.

Lots of tech can identify ctDNA in blood - Illumina, Thermo Fisher etc. I know that we can offer both ctDNA and CTC testing from the same blood sample which is great and which I'm sure will ultimately be a great revenue earner. My point is that co.'s like BioNTech aren't going to suddenly switch to the new approach of liquid biopsy - it will take time.

Hi EC - I think it will take a lot for BioNTech and others to switch from their tried and trusted solid tissue biopsy method to liquid biopsy. It may happen eventually but won't be anytime soon IMO. This isn't a big deal anyways as the volumes will be low compared to the huge volumes that will arise from liquid biopsy as a means for ongoing monitoring patient cancer mutation status as treatment progresses.

Price action seems to indicate that there is a big buy order being worked IMO.

Scinv_temp as of the Proactive presentation on Wednesday evening 10 iSCIB1+ patients had been recruited i.e. 10 in 1 month.

Chester18 I believe that the dual CPI's are standard of care anyway so patients would already receive them. What has been approved is the addition of Modi1.

Results due 7th June (this info was recently posted on on Angle's website)